SRTA (Strata Critical Medical) EBIT: $-20.0 Mil (TTM As of Mar. 2026)


SRTA Strata Critical Medical Inc SRTA
70 GF Score
Price $5.37
GF Value $4.47
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strata Critical Medical EBIT?

Strata Critical Medical SRTA -2.63% 70 EBIT is $-20.0 Mil as of Mar. 2026. GuruFocus rates SRTA with a GF Score™ of 70/100 and a GF Value™ of $4.47 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Strata Critical Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-3.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-20.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Strata Critical Medical's annualized ROC % for the quarter that ended in Mar. 2026 was -4.82%. Strata Critical Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -13.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Strata Critical Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4.87%.

Strata Critical Medical  (NAS:SRTA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Strata Critical Medical's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-11.896 * ( 1 - 0% )/( (245.099 + 248.874)/ 2 )
=-11.896/246.9865
=-4.82 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=325.472 - 19.142 - ( 61.231 - max(0, 19.794 - 126.192+61.231))
=245.099

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=327.618 - 19.955 - ( 58.789 - max(0, 20.942 - 124.145+58.789))
=248.874

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Strata Critical Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.896/( ( (39.551 + max(45.819, 0)) + (44.282 + max(45.401, 0)) )/ 2 )
=-11.896/( ( 85.37 + 89.683 )/ 2 )
=-11.896/87.5265
=-13.59 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(39.958 + 0 + 25.003) - (19.142 + 0 + 0)
=45.819

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(39.602 + 0 + 25.754) - (19.955 + 0 + 3.5527136788005E-15)
=45.401

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Strata Critical Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-19.955/409.461
=-4.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strata Critical Medical EBIT Related Terms

Strata Critical Medical EBIT Historical Data

* Premium members only.

The historical data trend for Strata Critical Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strata Critical Medical EBIT Chart

Strata Critical Medical Annual Data
Trend Sep19 Sep20 Sep21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -24.09 -53.53 -68.12 -22.53 -22.35

Strata Critical Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.69 -4.95 -5.62 -6.41 -2.97

SRTA vs TOI, GMRS, CCRN: EBIT Comparison

For the Medical Care Facilities subindustry, Strata Critical Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strata Critical Medical EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Strata Critical Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Strata Critical Medical's EV-to-EBIT falls into.


SRTA
70GF Score
Strata Critical Medical Inc SRTA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strata Critical Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-20.0 Mil mean?
Strata Critical Medical (SRTA) has a EBIT of $-20.0 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Strata Critical Medical.
Is Strata Critical Medical's EBIT too high?
Strata Critical Medical's current EBIT is $-20.0 Mil. Overall, Strata Critical Medical has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strata Critical Medical's EBIT compare to TOI and GMRS?
Strata Critical Medical's EBIT of $-20.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Strata Critical Medical. Strata Critical Medical's current EBIT is $-20.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Critical Medical stock overvalued right now?
Based on GuruFocus' analysis, Strata Critical Medical (SRTA) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.47, compared to a current price of $5.37 — trading 20% above its estimated fair value. The current EBIT is $-20.0 Mil. Strata Critical Medical's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Strata Critical Medical (SRTA), the current EBIT is $-20.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strata Critical Medical (SRTA) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Critical Medical stock appears to be overvalued. The current stock price of $5.37 is trading 20% above its estimated GF Value™ of $4.47. GuruFocus considers Strata Critical Medical to be Modestly Overvalued.

Key valuation signals for SRTA:

  • EBIT: $-20.0 Mil
  • GF Value™: $4.47 vs. price of $5.37 (20% above fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the SRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strata Critical Medical Business Description

Address 31 Hudson Yards, 14th Floor, New York, NY, USA, 10001
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
70GF Score

Get the complete analysis for SRTA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.37
Price
$4.47
GF Value